PIK3CG and neoplasm: Thus, novel therapeutic options targeted PI3K/AKT pathway promote apoptosis or cell death, as well as regulate tumor microenvironment (TME) of HL cells in preclinical studies [300–302], and patients may get beneficial strategy in clinical trials of PI3K/AKT inhibitors (Tables 2 and 3).